Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
23.01. | Tris Pharma announces positive results from ALLEVIATE-1 trial of cebranopadol | ||
22.01. | Innovative Health Initiative launches a trial aimed at ending Crohn's Disease | ||
22.01. | AstraZeneca receives positive recommendations for lung cancer treatments | ||
21.01. | AlzeCure's NeuroRestore ACD856 to be presented at AD/PD 2025 | ||
21.01. | EC approves lazertinib in combination with amivantamab for NSCLC patients | ||
20.01. | UK sees 70% increase in phase I advanced therapy clinical trials in 2024 | ||
20.01. | Datapharm expands into US market through partnership with phactMI | ||
16.01. | Biofidelity and CellCarta partner to deploy Aspyre Lung in global clinical trials | ||
16.01. | Actinogen boosts trial with Cambridge Cognition's digital suite | ||
15.01. | Owlstone Medical announces $27 million USD first close in Series E financing round | ||
15.01. | Oxford Drug Design achieves in vivo validation for novel cancer treatment | ||
14.01. | Pheno Therapeutics granted trial authorisation for MS candidate | ||
14.01. | Grifols pioneers high-tech analysis of plasma bank to detect Parkinson's disease | ||
13.01. | AI set to revolutionise pharmaceutical R&D says GlobalData | ||
13.01. | Gilead and LEO Pharma partner to develop oral STAT6 program | ||
09.01. | New therapy hope for prostate cancer patients | ||
09.01. | NICE recommends olaparib for BRCA-mutated breast cancer treatment | ||
08.01. | Cambridge Cognition highlights positive Cantab results | ||
08.01. | Angelini Ventures co-leads Series A financing in Neumirna Therapeutics | ||
07.01. | Novartis gene therapy set to enhance SMA treatment | ||
07.01. | Merck unveils new cyber-physical trust platform at CES 2025 | ||
06.01. | New prostate cancer test cuts biopsies by 50% in US | ||
06.01. | Amgen's lung cancer treatment gets conditional approval | ||
03.01. | NHS Confederation welcomes social care commission announcement | ||
03.01. | FDA approves Sequana Medical's Alfapump for ascites treatment |